000 | 01905 a2200529 4500 | ||
---|---|---|---|
005 | 20250514035248.0 | ||
264 | 0 | _c20020726 | |
008 | 200207s 0 0 eng d | ||
022 | _a0012-1797 | ||
024 | 7 |
_a10.2337/diabetes.51.7.2249 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aFreshwater, Jason D | |
245 | 0 | 0 |
_aElevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. _h[electronic resource] |
260 |
_bDiabetes _cJul 2002 |
||
300 |
_a2249-55 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xpharmacology |
650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
650 | 0 | 4 | _aBody Weight |
650 | 0 | 4 | _aCyclooxygenase 1 |
650 | 0 | 4 | _aCyclooxygenase 2 |
650 | 0 | 4 | _aCyclooxygenase 2 Inhibitors |
650 | 0 | 4 |
_aCyclooxygenase Inhibitors _xadministration & dosage |
650 | 0 | 4 |
_aDiabetes Mellitus, Experimental _xphysiopathology |
650 | 0 | 4 |
_aDinoprostone _xcerebrospinal fluid |
650 | 0 | 4 | _aEndothelin Receptor Antagonists |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFormaldehyde _xtoxicity |
650 | 0 | 4 |
_aHyperalgesia _xcerebrospinal fluid |
650 | 0 | 4 |
_aIndomethacin _xpharmacology |
650 | 0 | 4 | _aInjections, Spinal |
650 | 0 | 4 |
_aIsoenzymes _xmetabolism |
650 | 0 | 4 | _aMembrane Proteins |
650 | 0 | 4 |
_aPain _xchemically induced |
650 | 0 | 4 |
_aProstaglandin-Endoperoxide Synthases _xcerebrospinal fluid |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Sprague-Dawley |
650 | 0 | 4 | _aReceptor, Endothelin A |
650 | 0 | 4 | _aReference Values |
650 | 0 | 4 |
_aSpinal Cord _xenzymology |
700 | 1 | _aSvensson, Camilla I | |
700 | 1 | _aMalmberg, Annika B | |
700 | 1 | _aCalcutt, Nigel A | |
773 | 0 |
_tDiabetes _gvol. 51 _gno. 7 _gp. 2249-55 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.2337/diabetes.51.7.2249 _zAvailable from publisher's website |
999 |
_c11981356 _d11981356 |